Nir Melamed

Nir Melamed

Auto-generated profile, based on publicly available information

Nir Melamed

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
Liran HierschLiran Hiersch
Liran Hiersch
HBHoward Berger
Howard Berger
RORania Okby
Rania Okby
JRJoel G. Ray
Joel G. Ray
MGMichael Geary
Michael Geary
NMNir Melamed
Nir Melamed

1 February 2018 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
LHLiran Hiersch
Liran Hiersch
NMNir Melamed
Nir Melamed

30 September 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
NMNir Melamed
Nir Melamed
EAElizabeth Asztalos
Elizabeth Asztalos
KMKellie Murphy
Kellie Murphy
AZArthur Zaltz
Arthur Zaltz
DRDonald A. Redelmeier
Donald A. Redelmeier
JBJon Barrett
Jon Barrett
Objective: An increasing proportion of fetuses are exposed to antenatal corticosteroids (ACS). Despite their immediate beneficial effects, the long-term safety of ACS has been an ongoing source of concern. In the current study, we assessed the likelihood of neurodevelopmental problems among term infants exposed to ACS earlier in pregnancy compared with non-exposed term infants. Design: Retrospective cohort study (2006–2011). Median duration of follow-up was 7.8 (IQR 6.4–9.2) years. Setting: Population-based study, Ontario, Canada. Participants: All live singleton infants born at term (≥37 0/7 weeks gestation) (n=529 205). Exposure: ACS during pregnancy. Primary and secondary outcome measures: A composite of diagnostic or billing codes reflecting proven or suspected neurodevelopmental problems during childhood including audiometry testing, visual testing or physician service claim with a diagnosis code related to a suspected neurocognitive disorder. Results: At 5 years of age, the cumulative rate for the primary outcome was higher among infants exposed to ACS compared with non-exposed infants: 61.7% (3346/5423) vs 57.8% (302 520/523 782), respectively (p<0.001; number needed to harm (NNH)=25, 95% CI 19 to 38; adjusted HR (aHR) 1.12, 95% CI 1.08 to 1.16). Similar findings were observed for each of the individual components of the primary outcome: 15.3% vs 12.7% for audiometry testing (p<0.001; NNH=39, 95% CI 29 to 63; aHR 1.18, 95% CI 1.11 to 1.25); 45.4% vs 43.5% for visual testing (p=0.006; NNH=54, 95% CI 31 to 200; aHR 1.08, 95% CI 1.04 to 1.12) and 25.8% vs 21.6% for suspected neurocognitive disorder (p<0.001; NNH=24, 95% CI 19 to 33; aHR 1.16, 95% CI 1.10 to 1.21). Conclusions: We found an association among term infants between exposure to ACS during pregnancy and healthcare utilisation during childhood related to suspected neurocognitive and neurosensory disorders.

1 October 2016 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
NMNir Melamed
Nir Melamed
JSJyotsna Shah
Jyotsna Shah
EYEugene W. Yoon
Eugene W. Yoon
EPErmelinda Pelausa
Ermelinda Pelausa
SLShoo K. Lee
Shoo K. Lee
AKAndrzej Kajetanowicz
Andrzej Kajetanowicz

1 September 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
LPLeslie K. Proctor
Leslie K. Proctor
JKJulia Kfouri
Julia Kfouri
Liran HierschLiran Hiersch
Liran Hiersch
AAAmir Aviram
Amir Aviram
AZArthur Zaltz
Arthur Zaltz
NMNir Melamed
Nir Melamed

1 November 2016 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
NMNir Melamed
Nir Melamed
APAlex Pittini
Alex Pittini
LHLiran Hiersch
Liran Hiersch
YYYariv Yogev
Yariv Yogev
Steven J KorzeniewskiSteven J Korzeniewski
Steven J Korzeniewski
JBJon Barrett
Jon Barrett